Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacological abnormalities in atopic dermatitis.

J M Hanifin1

  • 1Oregon Health Sciences University, Portland.

Allergy
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pioneers in Dermatology and Venereology: an interview with Jon Hanifin, M.D.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019
Same author

Initial validation of the Burden of Disease in Atopic Eczema instrument, a quality-of-life measure for adult atopic dermatitis.

The British journal of dermatology·2018
Same author

Altered composition of epidermal lipids correlates with Staphylococcus aureus colonization status in atopic dermatitis.

The British journal of dermatology·2017
Same author

What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study.

The British journal of dermatology·2015
Same author

Inadequate response to ustekinumab in atopic dermatitis - a report of two patients.

Journal of the European Academy of Dermatology and Venereology : JEADV·2014
Same author

Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME).

The British journal of dermatology·2014

Atopic dermatitis involves cyclic nucleotide abnormalities, specifically low cyclic AMP due to elevated phosphodiesterase. This leads to increased histamine release and IgE synthesis, suggesting phosphodiesterase inhibitors as a potential therapy.

Area of Science:

  • Dermatology
  • Immunology
  • Biochemistry

Background:

  • Atopic dermatitis (AD) is associated with various physiological and pharmacological abnormalities.
  • Previous research suggests a role for cyclic nucleotide dysregulation in AD pathogenesis.

Purpose of the Study:

  • To investigate the role of cyclic nucleotide abnormalities in atopic dermatitis.
  • To explore the potential of phosphodiesterase inhibitors as a therapeutic strategy for AD.

Main Methods:

  • Analysis of leukocyte cyclic AMP-phosphodiesterase levels in patients with atopic dermatitis.
  • Assessment of functional parameters including basophil histamine release and in vitro IgE synthesis.
  • Evaluation of the effects of phosphodiesterase inhibitors in vitro and in clinical settings.

Related Experiment Videos

Main Results:

  • Elevated leukocyte cyclic AMP-phosphodiesterase was observed in atopic dermatitis, leading to reduced intracellular cyclic AMP levels.
  • Low cyclic AMP levels correlated with increased basophil histamine release and in vitro IgE synthesis.
  • In vitro and clinical application of phosphodiesterase inhibitors corrected these abnormal parameters.

Conclusions:

  • Cyclic nucleotide abnormalities, particularly low cyclic AMP due to elevated phosphodiesterase, are implicated in the pathophysiology of atopic dermatitis.
  • Phosphodiesterase inhibition demonstrates therapeutic potential for correcting key functional defects in atopic dermatitis.
  • Targeting phosphodiesterase may offer a novel therapeutic direction for managing atopic dermatitis.